Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04772911 · ClinicalTrials.gov registry record
Multicenter Phenotype-Genotype Analysis of Vascular Stains to Optimize Treatment Utilizing Optical Coherence Tomography
A clinical trial of Vascular Stains, sponsored by University of Wisconsin, Madison.
- Active
- Registry status
- 73
- Enrollment target
- 2
- Study locations
NCT04772911: Active study of Vascular Stains, sponsored by University of Wisconsin, Madison.
NCT04772911 is a study of Vascular Stains that is active but no longer recruiting, run by University of Wisconsin, Madison. The registered enrollment target is 73 participants. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04772911, a study of Vascular Stains, is active but no longer recruiting, sponsored by University of Wisconsin, Madison.
- ACTIVE NOT RECRUITING
- Registry status
- 73 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this research study is to develop a better understanding of vascular stains and to improve the usual laser treatment for vascular stain by using optical coherence tomography (OCT). A total of about 130 people will participate in this study.
Primary Outcome
Targeted next generation sequencing (NGS) using a hybrid capture approach will be performed on DNA samples from affected tissues. OCT measurements of blood vessel size will be compared to genotype derived from biospecimen.
Conditions Studied
Interventions
- DEVICE Optical Coherence Tomography (OCT)
Study Locations (2)
California
- University of California - Irvine
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2021-03-11 |
| Est. Completion | 2027-04 |
What the registry record for NCT04772911 still lists
NCT04772911 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 73 participants, a relatively small participant target.
The record links to 1 condition, with Vascular Stains appearing as the primary indexed condition, and to 1 intervention - of which Optical Coherence Tomography (OCT) is the first listed.
NCT04772911 reports a single indexed study location in California, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04772911 about?
NCT04772911 is a clinical study titled "Multicenter Phenotype-Genotype Analysis of Vascular Stains to Optimize Treatment Utilizing Optical Coherence Tomography". The purpose of this research study is to develop a better understanding of vascular stains and to improve the usual laser treatment for vascular stain by using optical coherence tomography (OCT). A total of about 130 people will participate in this study.
What is the current status of trial NCT04772911?
This trial is currently active not recruiting. The enrollment target is 73 participants. The study started on 2021-03-11. Estimated completion is 2027-04.
What conditions does trial NCT04772911 study?
This clinical trial studies the following conditions: Vascular Stains.
What interventions are being tested in trial NCT04772911?
The interventions under investigation include: Optical Coherence Tomography (OCT) (DEVICE).
Who is sponsoring clinical trial NCT04772911?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04772911 being conducted?
This trial has 2 study locations across California, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI